Breaking News, Collaborations & Alliances

WuXi Advanced Therapies and A*STAR Form Partnership

To advance cell and gene therapy in the Asia-Pacific region.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR’s Bioprocessing Technology Institute (BTI), formed a new partnership to bring WuXi ATU’s proprietary Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to the Asia-Pacific region. This partnership aims to foster scientific innovation in cell and gene therapy, and establish a joint professional development program to train and develop the next generation of scientists and engineers ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters